The microbial derivative AHR ligand tapinarof has shown clinically meaningful dose-dependent improvements in phase IIb trials in both psoriasis and atopic dermatitis (Peppers et al., 2019; Robbins et al., 2019); it is currently being tested in phase III trials for psoriasis. This evidence concerns the gene AHR and psoriasis.